At Celgene, we believe patients should have the opportunity, regardless of their location or financial resources, to benefit from advances in prevention, diagnosis and treatment of disease. Celgene Global Health (CGH), founded in 2009, collaborates with partners around the globe to find innovative solutions for healthcare challenges in the developing world. This work is based on our belief that innovative therapies and healthcare partnerships are essential components to long-term progress and prosperity around the globe.
CGH is screening our diverse chemical library against the pathogens for neglected diseases of the developing world (DDW). Diseases being studied include:
- Human African Trypanosomiasis (HAT) or Sleeping Sickness
- Tuberculosis (TB)
- Lymphatic Filariasis (LF)
- Viral Haemorrhagic Fevers (VHFs)
CGH is collaborating with Product Development Partnerships (PDPs), global academic institutions, non government organisations (NGOs), public/private funding organisations, contract research organisations (CROs), and other pharmaceutical organisations to evaluate our proprietary compounds for activity in neglected diseases. CGH programmes are in different stages of development from screening to lead optimisation to clinical trials.
Recently, CGH expanded its collaboration with Drugs for Neglected Diseases initiative (DNDi) to identify and optimise new therapy candidates for the treatment of neglected tropical diseases (NTDs). Since 2011, CGH and DNDi have collaborated on the screening of CGH’s compound library for activity against neglected tropical diseases. With this expanded collaboration, CGH and DNDi will work together to identify and optimise potential therapeutic candidates for leishmaniasis, HAT, chagas disease, and lymphatic filariasis.
CGH is actively applying modern discovery efforts in a collaboration with Medicines for Malaria Venture (MMV) to identify novel therapies for blood and liver-stage malaria. The world-wide disease burden for malaria is enormous, with more than half the world at risk and the possible threat of resistance to existing therapies. In collaboration with MMV, we have discovered several novel classes of anti-malarial compounds from an erythrocyte whole cell phenotypic screen against the major pathogen, Plasmodium falciparum.
A CGH discovery and development collaboration with Advinus Therapeutics Ltd focuses on therapies for visceral leishmaniasis (VL), the second-largest parasitic killer in the world, with an estimated 500,000 cases per year. The collaboration was formed to address patient needs that are not met with the current treatments available and highlights the experience and expertise of both organisations including medicinal chemistry, adsorption, distribution metabolism and excretion (ADME) and drug metabolism and pharmacokinetics (DMPK) expertise, and design of in vivo proof-of-concept models.
CGH has also teamed with the H3-D Drug Discovery and Development Center at the University of Cape Town (UCT) in South Africa to identify and develop next generation therapies for patients with TB. This joint therapy discovery program will identify novel therapies for the treatment of TB through active compounds identified from the Celgene chemical library.
During the past several years, CGH has been working with the Indiana University School of Medicine and Moi University Teaching and Referral Hospital in Eldoret, Kenya. Since 1989, Moi University School of Medicine, Moi Teaching and Referral Hospital and a consortium of North American academic health centers led by Indiana University have worked together to deliver health services, conduct health research and develop leaders in health care for both North America and Africa. The institutional partners are collectively named the Academic Model Providing Access to Healthcare (AMPATH).Today, in partnership with the Kenyan Ministry of Health and the United States Government, AMPATH is expanding from an HIV focus to address critical needs for primary healthcare, chronic disease care and specialty care. CGH is providing support to AMPATH within their oncology programme in the areas of patient/drug information, patient care, pharmacy database expansion and pharmacy rendering.
CGH is providing support to the University of Colorado (CU). Under the auspices of the Colorado School of Public Health (CSPH), the Center for Global Health at CU has built valuable relationships with universities and clinics in several low and middle income settings including Peru, Guatemala, Vietnam and Indonesia. These relationships will enable healthcare professionals from these developing countries to participate in Global Health Fellowships at the Anschutz Medical Campus at CU. Through these fellowships, which range from a month to a semester, up-and-coming investigators will gain targeted mentoring and hands on experience unavailable in their home countries.
World Child Cancer
The partnership that Celgene has built with UK based charity World Child Cancer goes beyond financial donations. For example, Celgene UK and Ireland have been donating soft toys to children at each of the projects that World Child Cancer supports and they have also been involved in sponsored walks, donated to raffles and taken part in marathons and bike-a-thons to name just a few. Celgene has been recognised by World Child Cancer as their official corporate sponsor, and was featured in the Financial Times newspaper advertisement focusing on the organisation as their charity of choice during their Annual Seasonal Appeal in December 2013.
World Child Cancer is committed to improving the lives of children with cancer across the world. Celgene has been a supporter of World Child Cancer since 2011. This organisation treats children with cancer in developing countries through their network of international hospitals and volunteer specialists with teams on the ground. World Child Cancer is one of the few organisations involved in the twinning partnerships between pediatric oncology units around the world. Current projects are taking place in Bangladesh, Malawi, Colombia, Ghana, the Philippines and Cameroon.
To find out more please visit: https://www.worldchildcancer.org/
Date of preparation: May 2015